T-bet is a critical determinant in the instability of the IL-17-secreting T-helper phenotype
IL-23, an IL-12-related cytokine, induces an IL-17-secreting T-helper phenotype that is involved in autoimmune diseases and host defense against certain pathogens. Although the transcription factors required for development of IL-23-stimulated cells are unknown, we show that T-bet is a critical nega...
Saved in:
Published in | Blood Vol. 108; no. 5; pp. 1595 - 1601 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Washington, DC
Elsevier Inc
01.09.2006
The Americain Society of Hematology 2006 by The American Society of Hematology |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | IL-23, an IL-12-related cytokine, induces an IL-17-secreting T-helper phenotype that is involved in autoimmune diseases and host defense against certain pathogens. Although the transcription factors required for development of IL-23-stimulated cells are unknown, we show that T-bet is a critical negative regulator of the IL-23-primed T-cell phenotype, which we term Th1β. Th1 or Th1β Tbx21-/- cultures secrete higher than WT levels of IL-17 in response to T-cell receptor (TCR) or IL-23 + IL-18 stimulation. Ectopic T-bet expression in Th1β cells promotes IFN-γ secretion but decreases IL-17 production. Although antigen-receptor stimulation of Th1β cells stimulates IL-17 production, it also induces the IFN-γ-independent expression of T-bet and progression to a Th1 cytokine secretion pattern. T-bet is required for the progression to the Th1 phenotype, because Tbx21-/- Th1β cultures maintain the IL-17-secreting phenotype after 2 weeks of culture. Addition of IFN-γ to Tbx21-/- Th1β cultures cannot recover the progression to the Th1 phenotype, suggesting T-bet, rather than IFN-γ, mediates Th1β to Th1 progression. The transient nature of the Th1β phenotype suggests that these cells are a component of type I immunity and that T-bet expression is a critical determinant of Th1 versus Th1β cell fate. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734. Prepublished online as Blood First Edition Paper, May 2, 2006; DOI 10.1182/blood-2006-04-015016. A.N.M. and D.G.Z. are predoctoral fellows of the American Heart Association. Reprints: Mark H. Kaplan, Departments of Pediatrics, and Microbiology and Immunology, Indiana University School of Medicine, Herman B. Wells Center for Pediatric Research, Riley Hospital for Children, 702 Barnhill Dr, RI 2600, Indianapolis, IN 46202; e-mail: mkaplan2@iupui.edu. Supported by the National Institutes of Health (NIH) Grants AI45515 (M.H.K.), T32DK007519 (H.C.C.), and AI50837 (G.S.K.); and by the Indiana Genomics Initiative of Indiana University (partially supported by the Lilly Endowment) (M.H.K.). |
ISSN: | 0006-4971 1528-0020 |
DOI: | 10.1182/blood-2006-04-015016 |